Skip to main content
  1. Home
    /
  2. IPO
    /
  3. Himalaya Nutravedics India IPO
Himalaya Nutravedics India IPO
2.77xsubscribed

Himalaya Nutravedics India IPO

listed
₹2.40LMin. investment

Himalaya Nutravedics India Limited IPO Details

Price range₹100 – ₹106
IPO type
SME
Lot size1200 shares
Issue size₹26Cr
Red Herring Prospectus
Read
Market cap
₹93.35CrLower than sector avg
RevenueApr 2025 - Mar 2026
₹43.06CrLower than sector avg
Growth rate3Y CAGR
72.76%

Himalaya Nutravedics India IPO Subscription Status

Date
QIB
NII
Retail
Total
22-Sep-26
0.0 times (X)
0.41 times (X)
0.16 times (X)
0.13 times (X)
23-Sep-26
0.0X
1.47X
0.67X
0.51X
24-Sep-26
1.0X
11.48X
2.54X
2.77X

As on 22-Sep-26, 5:30 PM

Himalaya Nutravedics India IPO Timeline

  1. Pre-apply
    21 Sep 2026
  2. Bid start
    22 Sep 2026
  3. Bid end
    24 Sep 2026
  4. Allotment
    25 Sep 2026
  5. Release of funds
    28 Sep 2026
  6. Demat transfer
    28 Sep 2026
  7. Listing
    29 Sep 2026

About Himalaya Nutravedics India Limited

Himalaya Nutravedics India manufactures, markets and distributes Ayurvedic and nutraceutical formulations in India and undertakes third-party contract manufacturing for other Ayurvedic and nutraceutical companies.
Incorporated on June 16, 2022, it commenced manufacturing in September 2022 at Cherlapally, Hyderabad. Its portfolio covers classical Ayurvedic formulations, proprietary Ayurvedic formulations and nutraceutical supplements in softgel and hardgel capsules, tablets, liquid orals, medicated oils and protein powders.
The company uses a hybrid model comprising own-brand products and third-party manufacturing. Own-brand revenue rose to 51.1% of FY26 revenue, from 19.6% in FY25 and 28.1% in FY24; third-party manufacturing contributed 48.8%, 80.3% and 71.9%, respectively.
Own-brand products are marketed through a doctor-centric, prescription-led offline model supported by stockists and super-stockists, while contract manufacturing is executed against client purchase orders and specifications. Softgel capsules generated 59.7% of FY26 revenue, medicated oils 29.9%, tablets 7.6% and other products 2.6%.
The company operates one integrated leased manufacturing facility of about 12,544 sq. ft. with around 63 machines and currently runs one eight-hour shift. Per-shift installed capacity is 400,000 softgels, 3,000 bottles of medicated oil, 150,000 tablets, 500 bottles of liquid orals, 150,000 hardgels and 200 bottles of protein powder. FY26 capacity utilisation was 63.7% for softgels, 90.2% for medicated-oil bottles, 17.8% for tablets, 13% for liquid-oral bottles, 4.2% for hardgels and 10.8% for protein-powder bottles.
The company marketed products across 17 states as of March 31, 2026. Kerala contributed 49.3% of FY26 revenue, followed by Gujarat at 13.2%, Uttar Pradesh at 11.6%, Telangana at 9.4% and Andhra Pradesh at 6.2%. Third-party manufacturing is concentrated in Kerala, which contributes about 90% of that segment's revenue.

Checklist

Quality analysis
Revenue growth
Company valuation
Earnings expansion
Risk analysis
Debt to Equity ratio
Promoter holdings
Shares pledged
The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily

Objectives of Himalaya Nutravedics India Limited IPO

Working capital requirements
51.80%
The company will utilise upto ₹13.75 crore to fund working capital requirements
Investment in marketing & sales expansion
28.30%
Up to ₹7.50 Cr will be invested in branding, digital marketing, and sales growth.
General corporate purposes
19.80%
Part of the IPO proceeds will be used for general corporate purposes and issue expenses

Compare

CompanyRevenue*3Y growthPATMarket capP/E ratioD/E ratio
This IPO₹43.06Cr72.76%₹7.38Cr₹93.35Cr8.800.31
This sector (avg.)₹1,331.47Cr0%₹193.4Cr₹10,914.84Cr60.870.43
₹52,578.44Cr---₹10,980.1Cr₹3,82,765.9Cr36.980.03
₹9,360Cr---₹2,191Cr₹1,60,635Cr64.600
₹11,516.09Cr---₹1,911.25Cr₹1,34,051.5Cr62.640.42

*Revenue for financial year 2025-26. Lower P/E and D/E ratios are generally preferred.

Himalaya Nutravedics India IPO Contact Details

Company NameHimalaya Nutravedics India Limited

How to apply for Himalaya Nutravedics India IPO?

  1. Step 1

    Log in to your Upstox account to access IPO investments. Next, select the current IPO section.

  2. Step 2

    Specify IPO details. Enter the number of lots and the price you wish to apply for.

  3. Step 3

    Enter UPI ID. After entering your UPI ID, click submit. This will place your bid with the exchange.

  4. Step 4

    Mandate Notification. Your UPI app will receive a mandate notification to block funds.

  5. Step 5

    Approve Request. Your funds will be blocked once you approve the mandate request on your UPI.

Himalaya Nutravedics India Limited IPO FAQs

Investors can apply for the Himalaya Nutravedics India IPO through their Demat account via the stock exchange or through their broker.
The issue size of the Himalaya Nutravedics India IPO is 26 Cr.
Pre-applying for an IPO allows you to submit your application before the official subscription period begins.
The IPO shares will typically list on major stock exchanges such as the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE), as specified in the IPO prospectus.
Himalaya Nutravedics India IPO will be open between 2026-09-22 and 2026-09-24.
Himalaya Nutravedics India IPO allotment date is 2026-09-28. For Himalaya Nutravedics India IPO allotment status check, you can visit the website of the registrar of the IPO.
For Himalaya Nutravedics India IPO, the IPO registrar is KFIN TECHNOLOGIES LIMITED. You can check Himalaya Nutravedics India IPO allotment status on the website of the registrar.
The shares are proposed to be listed on the BSE and NSE.
The Himalaya Nutravedics India IPO shares will typically be credited to your demat account one working day before the IPO's listing date, provided your application is successfully allotted.
The Himalaya Nutravedics India IPO lot size is 1200 and minimum order quantity is 2400.
Himalaya Nutravedics India IPO has set the price band for its IPO at 106 per equity share with a face value of 10.